FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132423959> ?p ?o ?g. }

• W2132423959 abstract "Children are most vulnerable to malaria. A pyronaridine-artesunate pediatric granule formulation is being developed for the treatment of uncomplicated Plasmodium falciparum malaria.This phase III, multi-center, comparative, open-label, parallel-group, controlled clinical trial included patients aged ≤12 years, bodyweight ≥5 to <25 kg, with a reported history of fever at inclusion or in the previous 24 h and microscopically-confirmed uncomplicated P. falciparum malaria. Patients were randomized (2:1) to pyronaridine-artesunate granules (60/20 mg) once daily or artemether-lumefantrine crushed tablets (20/120 mg) twice daily, both dosed by bodyweight, orally (liquid suspension) for three days.Of 535 patients randomized, 355 received pyronaridine-artesunate and 180 received artemether-lumefantrine. Day-28 adequate clinical and parasitological response (ACPR), corrected for re-infection using polymerase chain reaction (PCR) genotyping (per-protocol population) was 97.1% (329/339; 95% CI 94.6, 98.6) for pyronaridine-artesunate; 98.8% (165/167; 95% CI 95.7, 99.9) for artemether-lumefantrine. The primary endpoint was achieved: pyronaridine-artesunate PCR-corrected day-28 ACPR was statistically significantly >90% (P < .0001). Pyronaridine-artesunate was non-inferior to artemether-lumefantrine: treatment difference -1.8% (95% CI -4.3 to 1.6). The incidence of drug-related adverse events was 37.2% (132/355) with pyronaridine-artesunate, 44.4% (80/180) with artemether-lumefantrine. Clinical biochemistry results showed similar mean changes versus baseline in the two treatment groups. From day 3 until study completion, one patient in each treatment group had peak alanine aminotransferase (ALT) >3 times the upper limit of normal (ULN) and peak total bilirubin >2xULN (i.e. within the Hy's law definition).The pyronaridine-artesunate pediatric granule formulation was efficacious and was non-inferior to artemether-lumefantrine. The adverse event profile was similar for the two comparators. Pyronaridine-artesunate should be considered for inclusion in paediatric malaria treatment programmes.ClinicalTrials.gov: identifier NCT00541385." @default.
• W2132423959 created "2016-06-24" @default.
• W2132423959 creator A5002286185 @default.
• W2132423959 creator A5005365222 @default.
• W2132423959 creator A5008604633 @default.
• W2132423959 creator A5013139296 @default.
• W2132423959 creator A5018495262 @default.
• W2132423959 creator A5019211222 @default.
• W2132423959 creator A5021993036 @default.
• W2132423959 creator A5022466290 @default.
• W2132423959 creator A5025093827 @default.
• W2132423959 creator A5026917090 @default.
• W2132423959 creator A5028535305 @default.
• W2132423959 creator A5033676700 @default.
• W2132423959 creator A5034327185 @default.
• W2132423959 creator A5042629291 @default.
• W2132423959 creator A5053245213 @default.
• W2132423959 creator A5053671869 @default.
• W2132423959 creator A5068237755 @default.
• W2132423959 creator A5075726388 @default.
• W2132423959 date "2012-10-31" @default.
• W2132423959 modified "2023-10-18" @default.
• W2132423959 title "Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial" @default.
• W2132423959 cites W1951642591 @default.
• W2132423959 cites W1990484619 @default.
• W2132423959 cites W1993147489 @default.
• W2132423959 cites W2047082943 @default.
• W2132423959 cites W2052473982 @default.
• W2132423959 cites W2057463574 @default.
• W2132423959 cites W2062119651 @default.
• W2132423959 cites W2070076574 @default.
• W2132423959 cites W2103830263 @default.
• W2132423959 cites W2135011211 @default.
• W2132423959 cites W2144190756 @default.
• W2132423959 cites W2157912408 @default.
• W2132423959 cites W2159307889 @default.
• W2132423959 cites W2166357496 @default.
• W2132423959 cites W2397256145 @default.
• W2132423959 cites W4211010162 @default.
• W2132423959 doi "https://doi.org/10.1186/1475-2875-11-364" @default.
• W2132423959 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3566922" @default.
• W2132423959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23113947" @default.
• W2132423959 hasPublicationYear "2012" @default.
• W2132423959 type Work @default.
• W2132423959 sameAs 2132423959 @default.
• W2132423959 citedByCount "41" @default.
• W2132423959 countsByYear W21324239592013 @default.
• W2132423959 countsByYear W21324239592014 @default.
• W2132423959 countsByYear W21324239592015 @default.
• W2132423959 countsByYear W21324239592016 @default.
• W2132423959 countsByYear W21324239592017 @default.
• W2132423959 countsByYear W21324239592018 @default.
• W2132423959 countsByYear W21324239592019 @default.
• W2132423959 countsByYear W21324239592020 @default.
• W2132423959 countsByYear W21324239592021 @default.
• W2132423959 countsByYear W21324239592022 @default.
• W2132423959 countsByYear W21324239592023 @default.
• W2132423959 crossrefType "journal-article" @default.
• W2132423959 hasAuthorship W2132423959A5002286185 @default.
• W2132423959 hasAuthorship W2132423959A5005365222 @default.
• W2132423959 hasAuthorship W2132423959A5008604633 @default.
• W2132423959 hasAuthorship W2132423959A5013139296 @default.
• W2132423959 hasAuthorship W2132423959A5018495262 @default.
• W2132423959 hasAuthorship W2132423959A5019211222 @default.
• W2132423959 hasAuthorship W2132423959A5021993036 @default.
• W2132423959 hasAuthorship W2132423959A5022466290 @default.
• W2132423959 hasAuthorship W2132423959A5025093827 @default.
• W2132423959 hasAuthorship W2132423959A5026917090 @default.
• W2132423959 hasAuthorship W2132423959A5028535305 @default.
• W2132423959 hasAuthorship W2132423959A5033676700 @default.
• W2132423959 hasAuthorship W2132423959A5034327185 @default.
• W2132423959 hasAuthorship W2132423959A5042629291 @default.
• W2132423959 hasAuthorship W2132423959A5053245213 @default.
• W2132423959 hasAuthorship W2132423959A5053671869 @default.
• W2132423959 hasAuthorship W2132423959A5068237755 @default.
• W2132423959 hasAuthorship W2132423959A5075726388 @default.
• W2132423959 hasBestOaLocation W21324239591 @default.
• W2132423959 hasConcept C126322002 @default.
• W2132423959 hasConcept C203014093 @default.
• W2132423959 hasConcept C2776120307 @default.
• W2132423959 hasConcept C2778048844 @default.
• W2132423959 hasConcept C2778059366 @default.
• W2132423959 hasConcept C2778118209 @default.
• W2132423959 hasConcept C2778371730 @default.
• W2132423959 hasConcept C2778629330 @default.
• W2132423959 hasConcept C2780780316 @default.
• W2132423959 hasConcept C2908647359 @default.
• W2132423959 hasConcept C71924100 @default.
• W2132423959 hasConcept C90924648 @default.
• W2132423959 hasConcept C98274493 @default.
• W2132423959 hasConcept C99454951 @default.
• W2132423959 hasConceptScore W2132423959C126322002 @default.
• W2132423959 hasConceptScore W2132423959C203014093 @default.
• W2132423959 hasConceptScore W2132423959C2776120307 @default.
• W2132423959 hasConceptScore W2132423959C2778048844 @default.
• W2132423959 hasConceptScore W2132423959C2778059366 @default.
• W2132423959 hasConceptScore W2132423959C2778118209 @default.
• W2132423959 hasConceptScore W2132423959C2778371730 @default.
• W2132423959 hasConceptScore W2132423959C2778629330 @default.
• W2132423959 hasConceptScore W2132423959C2780780316 @default.

• next